MetaVia Inc. $MTVA

By Microcap Ledger desk · CIK 0001638287

Facts as of Oct 11, 2026, 08:17 AM UTC. Built from SEC filings and our own data. Small caps move fast; check the latest filings.

Snapshot

Exchange: Nasdaq Capital Market
Sector: Pharmaceutical Preparations
Headquarters: Cambridge, MA
Fiscal year end: December 31
Shares outstanding: 6,588,101 [10-Q 2026-08-06]
as of 2026-08-03

Sources: [10-K 2026-03-26]

What the company doesAI summary of filing

MetaVia Inc. is a clinical-stage biopharmaceutical company developing product candidates, primarily vanoglipel (DA-1241) and DA-1726, which are manufactured solely by Dong-A ST. The company is pre-revenue and relies on third-party contract research organizations to conduct preclinical studies and clinical trials, with no internal manufacturing capabilities. MetaVia intends to seek marketing approvals from regulatory authorities and eventually commercialize its product candidates in the U.S. and internationally, subject to significant regulatory, competitive, and operational risks. [10-K 2026-03-26]

Segments: Vanoglipel (DA-1241), DA-1726

Financial health

From XBRL company facts (USD)
Period	Revenue	Net income	Operating cash flow	Cash	Filing
6 months to Jun 2026	—	−$9.14M	−$8.02M	$12.63M	[10-Q 2026-08-06]
FY ended Dec 2025	—	−$12.97M	−$15.70M	$10.28M	[DEF 14A 2026-04-27]
FY ended Dec 2024	—	−$27.59M	−$24.71M	$16.02M	[DEF 14A 2026-04-27]

Quarterly cash burn: −$4.01M
Cash runway Estimate: ~9.5 months

Capital structure and dilution

Summary only. How these instruments work: Dilution & financing desk.

Share count
Date	Shares outstanding	Filing
2024-11-04	8,616,010	[10-Q 2024-11-07]
2025-03-17	8,654,869	[10-K 2025-03-20]
2025-05-14	19,564,214	[10-Q 2025-05-14]
2025-08-07	24,197,809	[10-Q 2025-08-07]
2025-11-05	24,214,788	[10-Q 2025-11-06]
2026-03-20	5,090,936	[10-K 2026-03-26]
2026-05-11	5,164,370	[10-Q 2026-05-14]
2026-08-03	6,588,101	[10-Q 2026-08-06]

Shelf registration: S-1 filed 2026-01-05; declared effective 2026-01-15 [S-1 2026-01-05]

Listing status

Current status: 2 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-11-26. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.

Date	Event	Details	Deadline	Filing
2025-11-26	8-K Item 3.01	Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing	—	[8-K 2025-11-26]
2025-05-30	8-K Item 3.01	Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing	—	[8-K 2025-05-30]

More on deficiency notices and uplistings: Listing status desk.

Who owns it

Recent Form 4 transactions
Date	Insider	Type	Shares	Price	Filing
2026-06-08	Tursi James Patrick	grant	17,186	—	[4 2026-06-08]
2026-06-08	Strickland D Gordon	grant	17,186	—	[4 2026-06-08]
2026-06-08	Salsbury Michael	grant	17,186	—	[4 2026-06-08]
2026-06-08	Groves Jason L	grant	17,186	—	[4 2026-06-08]
2026-06-08	Koven Andrew I	grant	17,186	—	[4 2026-06-08]
2026-06-08	Glickman Mark A	grant	17,186	—	[4 2026-06-08]
2026-01-23	Woodworth Marshall H	grant	28,000	—	[4 2026-01-27]
2026-01-23	Kim Hyung Heon	grant	32,000	—	[4 2026-01-27]

Catalysts and calendar

Recent filings and releases
Date	Type	Title
2026-09-09	8-K	Regulation FD disclosure; Other events
2026-08-06	10-Q	Quarterly report
2026-08-06	8-K	Results of operations; Regulation FD disclosure
2026-07-09	8-K	Regulation FD disclosure; Other events
2026-07-02	8-K	Other events
2026-07-02	424B5	Prospectus or prospectus supplement
2026-06-08	8-K	Director or officer change; Shareholder vote results
2026-06-08	8-K	Regulation FD disclosure; Other events
2026-05-27	8-K	Regulation FD disclosure
2026-05-18	8-K	Regulation FD disclosure
2026-05-15	13G	Beneficial ownership report (5%+ holder)
2026-05-14	10-Q	Quarterly report

Facts as of Oct 11, 2026, 08:17 AM UTC. Small caps move fast; check the latest filings.